arrow
G

George Christoff

Bulgarian Alliance for Clinical and Translational Allergy
H指数:24
被引数:2,575

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study

易得生物制剂与重症哮喘缓解及其他临床结局的关联:一项全球真实世界研究

2026-08-060
OA
Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments

变应性鼻炎及其对哮喘的影响(ARIA)-EAACI指南—2024–2025年修订版:第一部分—关于鼻内治疗的指南

2025-12-010
OAAI
Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024–2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms

过敏性鼻炎及其对哮喘的影响(ARIA)-EAACI 2024–2025指南的开发方法:从证据到决策框架到数字化共享决策算法

2025-11-210
OAAI
Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach

对重度哮喘患者T2炎症程度梯度下生物制剂应答的研究:一种数据驱动的生物标志物聚类方法

2025-09-020
OAAI
Prediction Pathway for Severe Asthma Exacerbations

严重哮喘急性发作的预测通路

CHEST
IF8.6
2025-05-190
OA
Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: A Pooled Analysis of Real-World Data

生物制剂启动对口服糖皮质激素使用的影响:国际重症哮喘注册登记研究与国际患者护理研究数据库的真实世界数据合并分析

2025-04-260
OAAI
Impact of biologic initiation on oral corticosteroids in the International Severe Asthma Registry and the Optimum Patient Care Research Database: a pooled analysis
2024-10-300
PRE
Phenotype and biomarkers in patients who initiated biologics therapy stratified by oral corticosteroid use in the International Severe Asthma Registry
2024-10-300
PRE
Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence-Assisted ARIA Care Pathways (ARIA 2024)

以人为中心的,数字化的,人工智能辅助的ARIA护理途径 (ARIA 2024) 的发展概念

2024-10-013
OAAI
Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults

成人重症哮喘生物治疗后临床缓解的定义和预测因素探讨

2024-10-018
OAAI
Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry
2024-10-012
OAAI
Exploring Definitions and Predictors of Response to Biologics for Severe Asthma
2024-09-018
OAAI
Allergen immunotherapy adverse events in adults with respiratory allergies-data from ADER: An EAACI task force report
2024-08-220
PRE
International Variation in Severe Exacerbation Rates in Patients With Severe Asthma
CHEST
IF8.6
2024-07-013
PRE
Real-world biologics response and super-response in the International Severe Asthma Registry cohort

国际重症哮喘登记队列中的真实世界生物制剂反应和超反应

2024-06-220
OAAI
Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma

重症哮喘患者的前生物T2-biomarker组合与对生物制剂的反应之间的关联

2024-04-196
OAAI
Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma
2024-02-0112
OA
Reply to Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry
2024-02-010
OAAI
Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study
2023-11-018
PRE
Real-world associations between outcomes and biomarkers in severe asthma patients treated with biologics
2023-10-270
PRE